1) 川崎富作. 指趾の特異的落屑を伴う小児の急性熱性皮膚粘膜淋巴症候群. アレルギー. 1967 ; 16 : 178-222.
3) Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008 ; 40 : 35-42.
4) 日本川崎病学会, 日本川崎病研究センター, 厚生労働科学研究難治性血管炎に関する調査研究班. 川崎病 診断の手引き改訂第6版. http://www.jskd.jp/info/pdf/tebiki201906.pdf
5) 高橋啓. 病理-冠動脈 (急性期・遠隔期) -. In : 日本川崎病学会, 編. 川崎病学. 東京 : 診断と治療社 ; 2018. p.37-41.
6) Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study) : a randomised, open-label, blinded- endpoints trial. Lancet. 2012 ; 379 : 1613-20.
7) Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006 ; 149 : 237-40.
8) Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007 ; 166 : 131-7.
9) Okada K, Hara J, Maki I, et al ; Osaka Kawasaki Disease Study Group. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009 ; 168 : 181-5.
10) Hamada H, Suzuki H, Oouchi Y, et al ; KAICA trial Investigators. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA) : a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019 ; 393 : 1128-37.
11) Tremolet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012 ; 161 : 506-12.
12) Minami T, Shiraishi H, Oka K, et al. Continuous infusion of Cyclosporin A in intravenous immunoglobulin resistant Kawasaki disease patients. Jichi Medical University Journal. 2011 ; 34 : 109-15.
13) Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008 ; 153 : 833-8.
14) 日本小児循環器学会学術委員会川崎病急性期治療ガイドライン作成委員会. 川崎病急性期治療ガイドライン (2020年改訂版). 日小循誌. 2020 ; 36 (suppl 1) : S1-29.
15) 日本循環器学会, 日本心臓血管外科学会, 日本川崎病学会, 他. 日本循環器学会/日本心臓血管外科学会合同ガイドライン2020年改訂版 川崎病心臓血管後遺症の診断と治療に関するガイドライン. 2020.